Vivamed has developed a novel, battery-less neuromodulation system for the treatment of obstructive sleep apnea (OSA), a condition affecting over 30 million adults in the U.S. and representing a ~$14B annual market. The system wirelessly stimulates the hypoglossal nerve to maintain upper-airway patency during sleep, eliminating the need for implanted batteries or lead tunneling. Vivamed’s approach enables a smaller implant, simplified implantation, and long device lifetime, while supporting closed-loop, patient-specific therapy through external sensing and control. The platform is designed to expand access to neuromodulation-based OSA therapy beyond current surgical and compliance-limited solutions.